Nontuberculous mycobacteria testing and culture positivity in the United States

Julia E. Marshall,Rachel A. Mercaldo,Ettie M. Lipner,D. Rebecca Prevots
DOI: https://doi.org/10.1186/s12879-024-09059-9
IF: 3.7
2024-03-07
BMC Infectious Diseases
Abstract:Nontuberculous mycobacteria (NTM) are environmental bacteria which may cause chronic lung disease. The prevalence of NTM pulmonary infection and disease has been increasing in the United States and globally. The predominant clinically relevant species of NTM in the United States are Mycobacterium avium complex (MAC) species and Mycobacterium abscessus . With the development of rapid species identification methods for NTM (e.g. PCR probes), more testing for NTM is being conducted through commercial labs, such as Laboratory Corporation of America (Labcorp), which provides deidentified real-time testing data to the Centers for Disease Control (CDC) pursuant to a data sharing agreement. Because NTM lung infections are not reportable in most states, other data sources are key to understanding NTM testing patterns, positivity rates, and species distributions to track infection trends and identify clinical care needs.
infectious diseases
What problem does this paper attempt to address?